Sticky Archives - ThyGeNEXT® + ThyraMIR®v2

Oncocytic (formerly Hürthle Cell) Thyroid Nodules: Risk-Stratification with ThyGeNEXT + ThyraMIRv2

Oncocytic thyroid nodules, formerly known as Hürthle cell nodules, can present a diagnostic challenge. These lesions are composed of cells with abundant eosinophilic cytoplasm caused by mitochondrial accumulation.1 Although malignant oncocytic tumors are relatively rare, they are clinically significant due to their aggressive behavior and high risk of recurrence and distant metastasis.1-3 Oncocytic thyroid carcinoma […]

Oncocytic (formerly Hürthle Cell) Thyroid Nodules: Risk-Stratification with ThyGeNEXT + ThyraMIRv2 Read More »

Enhanced Thyroid Nodule Risk Stratification Through microRNA Profiling: A Clinical Case Study

By admin

In a patient with an indeterminate thyroid nodule and no identified mutations, the use of microRNA signatures helped inform a high risk of malignancy. This clinical case highlights how microRNA profiling, when combined with mutational analysis, can provide deep insights to help improve the risk stratification of indeterminate thyroid nodules.1-3 Clinical Case Overview A 48-year-old

Enhanced Thyroid Nodule Risk Stratification Through microRNA Profiling: A Clinical Case Study Read More »

Confidently Risk-stratify Indeterminate Thyroid Nodules with ThyGeNEXT+ThyraMIRv2

By admin

The management of indeterminate thyroid nodules— i.e., nodules classified as Atypia of Undetermined Significance (Bethesda III) and Follicular Neoplasm (Bethesda IV)— continues to pose a substantial diagnostic challenge and often creates uncertainty in clinical decision-making.1 Historically, this uncertainty has led to diagnostic thyroid surgery for many patients with indeterminate cytology, potentially resulting in unnecessary procedures

Confidently Risk-stratify Indeterminate Thyroid Nodules with ThyGeNEXT+ThyraMIRv2 Read More »